Mucopolysaccharidosis Type VII (Sly Syndrome)
A rare inherited disorder caused by deficiency of the enzyme beta-glucuronidase, leading to progressive accumulation of glycosaminoglycans across multiple organ systems.
- Enzyme deficiency: beta-glucuronidase (GUSB)
- Autosomal recessive inheritance
- Multi-system involvement
- Specialist genetic and metabolic care
- Disease Group
- Lysosomal Storage Disorders
- Inheritance Pattern
- Autosomal Recessive (GUSB gene)
- Onset Range
- Prenatal to Adult, depending on severity
- Advanced Therapies
- Enzyme Replacement Therapy, HSCT, Gene Therapy Research
Condition Overview
Mucopolysaccharidosis Type VII (MPS VII), also known as Sly syndrome, is a rare lysosomal storage disorder caused by a deficiency of the enzyme beta-glucuronidase. This enzyme is needed to break down glycosaminoglycans (GAGs), complex sugar molecules found throughout connective tissue, bone, and organs. When the enzyme is missing or insufficient, GAGs accumulate progressively in cells, leading to organ enlargement, skeletal abnormalities, and in many cases, developmental and neurological involvement.
MPS VII spans a wide clinical spectrum, from a severe form presenting before or shortly after birth with non-immune hydrops fetalis, to milder, attenuated forms that may not be recognized until later childhood or adulthood. Because symptoms overlap with other mucopolysaccharidoses and storage disorders, accurate enzymatic and genetic testing is essential for diagnosis and management planning.
Early recognition matters because supportive interventions, multidisciplinary care, and in selected cases enzyme replacement therapy can meaningfully change the disease trajectory, particularly for skeletal, respiratory, and cardiac complications.
Types and Clinical Subtypes
MPS VII is generally described along a severity spectrum rather than as distinct discrete subtypes, though clinicians broadly group presentations as follows.
Symptoms and Signs
Symptoms reflect progressive GAG accumulation in connective tissue, bone, and organs, and vary considerably with disease severity.
Causes and Risk Factors
MPS VII is caused entirely by inherited genetic mutations; it is not linked to lifestyle, environment, or exposures.
Diagnosis and Investigations
Diagnosis combines clinical suspicion, biochemical testing, and genetic confirmation.
Disease Severity Stratification
MPS VII does not use a tumor-style staging system. Instead, clinicians classify disease severity to guide monitoring and treatment intensity.
Standard Treatment Options
Management is multidisciplinary and supportive, addressing each affected organ system while enzyme-targeted options are considered where available.
Advanced and Emerging Treatment Options
Research into enzyme replacement and gene-based approaches continues to expand options for MPS VII.
Enzyme Replacement Therapy
Recombinant beta-glucuronidase replacement
Intravenous enzyme replacement is approved in some regions and aims to reduce systemic GAG accumulation.
Cellular Therapy
Hematopoietic Stem Cell Transplant (HSCT)
HSCT has been used in select severe cases to provide a durable source of functional enzyme, though experience in MPS VII is more limited than in other MPS types.
Gene Therapy
Investigational gene therapy approaches
Early-phase research is exploring gene transfer strategies to restore beta-glucuronidase activity.
Biomarkers and Molecular Testing
Biochemical and genetic markers support diagnosis, carrier detection, and monitoring of disease burden.
When a Second Opinion May Be Important
Because MPS VII is rare and its severity varies widely, an additional specialist review can help confirm the diagnosis and refine the care plan.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Outcomes in MPS VII vary substantially based on disease severity at presentation and the organs involved. Early diagnosis and coordinated multidisciplinary care can meaningfully improve quality of life.
Supportive Care and Living with MPS VII
Comprehensive supportive care helps manage symptoms and maintain quality of life across the lifespan.
How CancerFax Helps You Explore Treatment Options
CancerFax can help families with MPS VII obtain specialist medical report review, coordinate second opinions, and connect with centers experienced in enzyme replacement therapy and stem cell transplant for rare lysosomal storage disorders.
Get a free case reviewFrequently Asked Questions
MPS VII is a rare inherited lysosomal storage disorder caused by deficiency of the enzyme beta-glucuronidase, leading to progressive accumulation of glycosaminoglycans in tissues throughout the body.
MPS VII is caused by mutations in the GUSB gene, inherited in an autosomal recessive pattern, meaning both parents must carry a mutated copy of the gene.
Early signs can include coarse facial features, hernias, hepatosplenomegaly, joint stiffness, and in severe cases, hydrops fetalis detected before birth.
Diagnosis typically involves urine GAG screening, confirmation of low beta-glucuronidase enzyme activity, and genetic testing of the GUSB gene.
There is currently no cure, but enzyme replacement therapy, stem cell transplant in select cases, and supportive multidisciplinary care can help manage the condition.
Yes. In families with a known GUSB mutation, prenatal testing can identify affected pregnancies, and severe cases may present with hydrops fetalis on ultrasound.
Care typically involves medical geneticists, metabolic specialists, orthopedists, cardiologists, pulmonologists, and ophthalmologists working together.
This varies by severity; some patients with attenuated disease have normal cognition, while severe forms may involve developmental delay.
Options include enzyme replacement therapy where available, supportive care for skeletal, respiratory, and cardiac complications, and in select severe cases, hematopoietic stem cell transplant.
Yes. CancerFax can help families review medical reports, coordinate second opinions with specialists experienced in lysosomal storage disorders, and connect with centers offering enzyme replacement therapy or stem cell transplant, including cross-border care coordination where needed.
Get Expert Guidance for MPS VII (Sly Syndrome)
Connect with specialists experienced in rare lysosomal storage disorders to review your medical reports and discuss treatment options.